Werkgroep Cardiologische centra Nederland

EMPULSE (Recruiting)

a Phase III trial to evaluate the effect on changes in NT-proBNP, safety and tolerability of once daily oral EMPaglilozin 10 mg compared to placebo, initiated in patients hospitalized for acUte decompensated heart faiLure who have been StabilizEd (EMPULSE)
Medicine
Empagliflozine
Population
Heart failure
Phase
III
Starting year
2019
More information
Clinicaltrials.gov